Agreement about Availability of Alternative Treatments for Innovative Drugs Assessed by the EMA and HTA Organizations

In conclusion, although there was high overall agreement between the EMA and HTA organizations about whether alternative treatments exist, there were differences in the types of treatment considered. Parallel joint scientific consultations could inform drug developers about relevant alternative treatments to facilitate patient access to innovative drugs.PMID:38505926 | DOI:10.1002/cpt.3252
Source: Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Authors: Source Type: research